Company Filing History:
2 out of 151 
1 out of 2,488 
1 out of 1,157 Years Active: 2015-2016
Title: Innovator Katharina Nora Steinitz: Pioneering FVIII Peptides for Hemophilia Care
Introduction
Katharina Nora Steinitz is a distinguished inventor based in Siegenfeld, Austria, known for her substantial contributions to medical science through her innovative research and patent development. With a total of two patents to her name, Steinitz has focused her efforts on addressing critical challenges in the treatment of hemophilia A.
Latest Patents
One of Katharina's latest breakthroughs is centered around FVIII peptides for immune tolerance induction and immunodiagnostics. This invention relates to peptides that can significantly reduce the immune response against FVIII or help induce tolerance to human FVIII in patients affected by hemophilia A. Furthermore, these innovative peptides serve dual purposes; they are instrumental for immunodiagnostic applications—allowing for the detection of FVIII-specific CD4 T cells. This capability is essential for monitoring patients during both replacement therapy and immune tolerance induction therapy.
Career Highlights
Katharina Nora Steinitz has garnered experience working with leading companies in the healthcare sector, including Baxalta GmbH and Baxter International Inc. Her tenure with these firms has played a crucial role in her professional development, enabling her to contribute meaningfully to advancements in hemophilia treatment.
Collaborations
Throughout her career, Katharina has collaborated with esteemed colleagues such as Paula Maria Wilhelmina van Helden and Birgit Maria Reipert. These partnerships have fostered a creative and innovative environment, often resulting in pioneering research and solutions to complex medical issues.
Conclusion
Katharina Nora Steinitz's work exemplifies the transformative potential of innovative research in the medical field. Her patents related to FVIII peptides not only address immediate healthcare needs but also pave the way for future advancements in the treatment of hemophilia A. Through her collaborations and career experience, she continues to make significant strides in improving patient outcomes and enhancing the quality of life for many individuals affected by this condition.